Is ORIC Pharmaceuticals Inc. (NASDAQ:ORIC) the Best Biotech Penny Stock to Buy According to Hedge Funds?
From Yahoo Finance: 2025-04-16 11:09:00
Recent news highlighted the departure of Peter Marks from the FDA, raising concerns about the review program’s future. His influence on vaccine approvals and the cell and gene therapy field is significant. Investors are urged to consider biotech stocks less reliant on FDA approval due to potential instability and delays in the approval process.
Stifel’s Paul Matteis suggests a cautious approach to biotech investments amidst FDA uncertainty. Recent personnel changes and departures could lead to short-term approval delays, prompting investors to seek companies with more predictable growth prospects. Commercial-stage firms are favored over those heavily reliant on FDA consistency for stability.
Investors are shifting focus to biotech companies with de-risked profiles and less dependence on FDA flexibility for growth. Matteis highlights the outperformance of companies tied to commercial launches rather than regulatory decisions in the current environment. The departure of key FDA personnel adds uncertainty, prompting a reevaluation of investment strategies within the sector.
ORIC Pharmaceuticals Inc. (NASDAQ:ORIC) is a clinical-stage biotech company focused on developing therapies to combat cancer resistance mechanisms. Their lead product candidate, ORIC-114, targets specific genetic alterations in Non-Small Cell Lung Cancer (NSCLC). The company ranks 11th on the list of best biotech penny stocks based on hedge fund activity.
ORIC Pharmaceuticals Inc. (NASDAQ:ORIC) is currently conducting a Phase 1b clinical trial for ORIC-114 in NSCLC patients with various genetic mutations. The trial aims to evaluate the safety and efficacy of the drug in different patient cohorts, including those who have progressed after prior treatment with specific inhibitors.
Investors interested in biotech penny stocks can benefit from following hedge fund activity. ORIC Pharmaceuticals Inc. (NASDAQ:ORIC) shows promise in the cancer therapy space, but alternative investments in AI stocks may offer higher returns over a shorter period. Consider exploring AI stocks trading at attractive valuations for potential growth opportunities.